| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1021772197 |
| P356 | DOI | 10.1007/S00262-014-1547-6 |
| P698 | PubMed publication ID | 24770667 |
| P2093 | author name string | Donald A Richards | |
| Thomas E Boyd | |||
| David A Smith | |||
| Alain C Mita | |||
| John J Nemunaitis | |||
| Alice S Bexon | |||
| Guillaume de La Bourdonnaye | |||
| Paul Conkling | |||
| David Wages | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 | ||
| Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer | Q33395621 | ||
| Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study | Q33406802 | ||
| Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial | Q34050239 | ||
| In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study | Q34194680 | ||
| In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study | Q35669197 | ||
| TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts | Q35894601 | ||
| Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease | Q36357360 | ||
| Cisplatin nephrotoxicity: a review | Q36910929 | ||
| Considerations for second-line therapy of non-small cell lung cancer | Q37080780 | ||
| Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer | Q37199995 | ||
| Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice | Q37729944 | ||
| An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity | Q37916588 | ||
| A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer | Q39903605 | ||
| A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer | Q42596227 | ||
| Design and analysis of phase I clinical trials | Q44888410 | ||
| Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun | Q45309210 | ||
| Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck | Q45732639 | ||
| Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. | Q46905280 | ||
| Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer | Q46972019 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erlotinib | Q418369 |
| toll-like receptor | Q408004 | ||
| bevacizumab | Q413299 | ||
| P304 | page(s) | 787-796 | |
| P577 | publication date | 2014-04-27 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy | |
| P478 | volume | 63 |
| Q38689153 | Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches |
| Q39377049 | Anti-tumor Activity of Toll-Like Receptor 7 Agonists |
| Q60939646 | Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity? |
| Q38882266 | Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis |
| Q26751254 | Immunotherapy for lung cancer |
| Q90233649 | Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression |
| Q96167094 | Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies |
| Q41997055 | TLR Agonists as Adjuvants for Cancer Vaccines. |
| Q93164877 | Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma |
| Q58547311 | Targeting macrophages: therapeutic approaches in cancer |
| Q55034836 | The revival of CpG oligonucleotide-based cancer immunotherapies. |
| Q47100766 | Toll-like receptor expression in human non-small cell lung carcinoma: potential prognostic indicators of disease. |
| Q28067939 | Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy |
| Q36231932 | p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways |
Search more.